Insulet Corporation $PODD Stock: Counterpoint Mutual Funds LLC Lowers Holdings

Key Points

• Counterpoint Mutual Funds cut its Insulet stake by 95.7% in the third quarter, selling 43,514 shares and retaining 1,945 shares valued at approximately $254,000.
• Analysts have lowered several price targets, with consensus calling for a “Hold” rating and an average target of $186.68. Ratings include 13 Buys, 12 Holds and one Sell.
• Insulet reported quarterly EPS of $1.66, beating estimates of $1.47, while revenue rose 23.5% year over year to $801.7 million. Shares opened at $141.96, near the lower end of their 52-week range.

Counterpoint Mutual Funds LLC reduced its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 95.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,945 shares of the medical instruments supplier's stock after selling 43,514 shares during the period. Counterpoint Mutual Funds LLC's holdings in Insulet were worth $254,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Insulet in the 2nd quarter valued at $1,018,582,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock worth $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Man Group plc bought a new stake in shares of Insulet during the 2nd quarter worth $78,746,000. Amundi lifted its position in shares of Insulet by 13.6% during the 2nd quarter. Amundi now owns 507,847 shares of the medical instruments supplier's stock worth $77,320,000 after buying an additional 60,929 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Insulet during the 2nd quarter worth $64,921,000.

Analysts Set New Price Targets

PODD has been the topic of several research analyst reports. UBS Group reduced their price objective on Insulet from $174.00 to $150.00 and set a "neutral" rating on the stock in a research note on Thursday, August 6th. Jefferies Financial Group lowered their target price on Insulet from $275.00 to $190.00 and set a "buy" rating for the company in a research note on Monday, October 12th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Insulet in a report on Tuesday, June 23rd. They issued a "buy" rating and a $190.00 target price for the company. Citigroup increased their target price on shares of Insulet from $165.00 to $172.00 and gave the stock a "neutral" rating in a report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and issued a $152.00 price target (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $186.68.

Insulet Stock Up 0.6%

Shares of NASDAQ:PODD opened at $141.96 on Tuesday. The company has a fifty day moving average of $140.54 and a 200-day moving average of $155.98. The company has a market capitalization of $9.84 billion, a PE ratio of 26.53, a price-to-earnings-growth ratio of 1.11 and a beta of 1.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. Insulet's revenue was up 23.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities analysts predict that Insulet Corporation will post 6.51 EPS for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.